Loading stock data…
PFE
$26.30-0.03 (-0.11%)
Pre-Market$26.58+0.28 (+1.06%)· Last close May 4
Pfizer Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pfizer Inc. in the Healthcare sector is trading at $26.30. The stock is currently 9% below its 52-week high of $28.75, remaining 4.2% above its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why PFE maintains its current momentum and trend strength. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHABBV
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$26.30
Potential Upside
4%
Whystock Fair Value$27.34
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus27 analysts
Buy
Mean target$29.00+10.3%
Range$24.00 – $36.00
Fundamentals
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$152.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.71
Beta
Defensive asset. Lower volatility than the S&P 500.
0.39
Div Yield
Strong income play. Yield provides a meaningful total return floor.
630.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.43%
Volume
Today's trading volume
34.46M
Recent News
Pfizer beats first quarter estimates on strong product growth
Investing.com -- Pfizer Inc. (NYSE:PFE) reported first-quarter earnings that exceeded Wall Street expectations, driven by strong performance from its recently launched and acquired products portfolio.
Stocks Rise Pre-Bell as Investors Await More Earnings, Monitor Middle East Developments
US equity futures were trending higher on Tuesday as traders await a fresh batch of corporate earnin
Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates
Pfizer shares rose slightly in premarket trading after the company delivered a first-quarter earnings beat and reaffirmed its full-year outlook. The drugmaker posted adjusted earnings of 75 cents a share, ahead of the 72 cents Wall Street had forecast. Pfizer reaffirmed its full-year guidance, which it initially provided in December.
Tech Earnings, Jobs Report: What to Watch This Week
Earnings season revs up the next few days as investors will hear from big companies including Advanced Micro Devices, CoreWeave, Pfizer and McDonald's. Data on the U.S. jobs market will also be watched closely, culminating in April nonfarm payroll numbers Friday.
AMD and Pfizer earnings, job openings, Fedspeak: What to Watch
Asking for a Trend Host Josh Lipton previews several of the biggest stories to come tomorrow, Tuesday, May 5, including earnings results from Advanced Micro Devices (AMD), Pfizer (PFE), and Anheuser-Busch Inbev (BUD); fresh labor data in the form of the latest Job Openings and Labor Turnover Survey (JOLTS) report; and commentary from Federal Reserve Vice Chair for Supervision Michelle Bowman and Governor Michael Barr.